CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adju

Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update. Business Updates Completed Dosin

SC 13G/A - CervoMed Inc. (0001053691) (Subject)

SC 13D - CervoMed Inc. (0001053691) (Subject)

SC 13G - CervoMed Inc. (0001053691) (Subject)

SC 13D - CervoMed Inc. (0001053691) (Subject)

SC 13D - CervoMed Inc. (0001053691) (Subject)

Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D

LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client's unsolicited offer, but LifeSci instead chose to launch a proxy contest against our highly qualified boardLifeSci's track record demonstrates a highly troubling pattern of self-dealing and stockholder value destruction, including more than $1.3 billion of stockholder losses in recent SPAC transactionsDiffusion's board and management are fully committed to maxi

Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended September 30, 2022, and provided a business update. "As previously announced, we formalized our efforts to identify and evaluate strategic opportunities during the

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client's Offer Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process Date of Diffusion's 2022 Annual Meeting of Stockholders Set for December 30, 2022 CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developin

CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the "Board") has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactional opportunities to better leverage the potential of trans sodium crocetinate ("TSC") and the Company's other assets. As part of the Company's previously disclosed, ongoing efforts to identify ac

•  Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022•  Reported Positive Effects in TSC Altitude Trial•  Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities•  Expected Cash Runway into First Quarter of 2024 CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended June 30, 2022, and provided a business update. Development Updates Aligned w

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate ("TSC") in newly diagnosed glioblastoma multiforme ("GBM") patientsCompany to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography ("PET") hypoxia imaging methodology with data expected within one year of study initiationDiffusion previously obtained Orphan Drug Designation for use of TSC in conjunction with radiotherapy for the treatment of GBM CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing nov

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise intervalTSC was safe and well-tolerated by all subjects with no serious adverse events reported CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.

4 - CervoMed Inc. (0001053691) (Issuer)

3 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

10-Q - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of

  On Thursday, 109 companies set new 52-week lows. 52-Week Low Highlights: The largest company in terms of market cap to set a new 52-week low was Nasdaq (NASDAQ:NDAQ). Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest company in terms of market cap to set a new 52-week low. Sarcos Technology (NASDAQ:STRC) shares dropped the most, trading down 417.35% to reach its new 52-week low. Cineverse (NASDAQ:CNVS) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Here is a list of stocks that set new 52-week lows on Thursday: Nasdaq (NASDAQ:NDAQ) stock achieved a new 52-week low on Thursday morning, hitting $48.90 and moving down 1.92%. Jazz P

  Friday's session saw 100 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: BioNTech (NASDAQ:BNTX) was the largest, in terms of market cap, to set a new 52-week low. Vyant Bio (NASDAQ:VYNT) was the smallest, in terms of market cap, to set a new 52-week low. Soligenix (NASDAQ:SNGX)'s stock came under the most pressure, trading down 47.37% to reach a new 52-week low. Barings BDC (NYSE:BBDC) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. On Friday, the following stocks broke to new 52-week lows: BioNTech (NASDAQ:BNTX) stock achieved a new 52-week low on Friday morning, hitting $1

  On Wednesday, 345 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Pfizer (NYSE:PFE) was the largest company by market cap to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Windtree Therapeutics (NASDAQ:WINT). SharpLink Gaming (NASDAQ:SBET) made the largest move down on the session, with shares plummeting 832.52% to reach its 52-week low. Hope Bancorp (NASDAQ:HOPE) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. The stocks that set new 52-week lows on Wednesday: Danaher (NYSE:DHR) shares made a new 52-week low of $227.07 on Wednesday. T

  On Monday, 76 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: CVB Financial (NASDAQ:CVBF) was the biggest company in terms of market cap to set a new 52-week low. Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest firm by market cap to set a new 52-week low. Biodexa Pharmaceuticals (NASDAQ:BDRX)'s stock moved significantly downwards, trading down 25.64% to reach a new 52-week low. Aeglea BioTherapeutics (NASDAQ:AGLE) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Here is a list of stocks that set new 52-week lows on Monday: CVB Financial (NASDAQ:CVBF) shares made a new 52-week low of $16.33 on Monday.

Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process   Diffusion received bids from more than 15 companies participating in review process LifeSci invited to participate in review process on same terms as all other bidders following submission of client's unsolicited offer, but LifeSci instead chose to launch a proxy contest against our highly qualified board LifeSci's track record demonstrates a highly troubling pattern of self-dealing and stockholder value destruction, including more than $1.3 billion of stockholder losses in recent SPAC transactions Diffusion's board and management are fully comm

LifeSci Special Opportunities Master Fund Ltd. ("LifeSci Special Opportunities" or "we"), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc. ("Diffusion" or the "Company") (NASDAQ:DFFN), or approximately 4.8% of the Company's outstanding shares, today issued a statement in response to the Company's misleading press release from November 14, 2022 and announced that it has nominated a slate of high quality director candidates for election at the Company's upcoming annual meeting to be held on December 30, 2022 (the "2022 Annual Meeting"). LifeSci Special Opportunities Statement "The Company's November 14, 2022 press release announcing that its board of directors (t

Diffusion Pharmaceuticals (NASDAQ:DFFN) reported quarterly losses of $(1.37) per share. This is a 77.13 percent increase over losses of $(5.99) per share from the same period last year.

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process Date of Diffusion’s 2022 Annual Meeting of Stockholders Set for December 30, 2022